Skip to main content
    V

    Verrica Pharmaceuticals Inc (VRCA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.14
    -0.06 (-1.88%)

    Market Cap: $54.97M

    Last updated: Nov 17, 2026 at 4:32 PM ET

    Verrica Pharmaceuticals Inc (VRCA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Verrica Pharmaceuticals (VRCA) has a market cap of $54.97M and an enterprise value of $52.99M. Its share count is up 124.50% from a year earlier. It kept -189.23% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 3.61% below the market cap, as cash exceeds debt.

    Market Cap$54.97M
    Enterprise Value$52.99M
    Latest price (Nov 17, 2026)$3.14

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 113.35% a year over 2 years.

    Shares Outstanding21.31M
    Shares Change (YoY)+124.50%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+113.35%

    Valuation Ratios

    The price to sales ratio is 2.9x. Its year-end P/S ranged from 0.5x to 280.6x from 2021 to 2025.

    P/S Ratio2.9x
    Forward P/S2.2x

    Price Statistics

    The stock is down 20.10% over 52 weeks and trades 21.11% below its 50-day average.

    Beta (1Y)2.23
    52-Week Change-20.10%
    1-Month Change-8.72%
    3-Month Change-37.07%
    6-Month Change-43.83%
    5-Year Change-97.34%
    Total Return (1Y)-20.10%
    Total Return (3Y CAGR)-55.27%
    Total Return (5Y CAGR)-51.15%
    Return vs SPY (1Y)-29.57%
    Max Drawdown (1Y)-66.04%
    Max Drawdown (3Y)-96.77%
    Sharpe Ratio (1Y)-0.22
    Correlation with SPY (1Y)0.33
    50-Day Average$3.98
    200-Day Average$5.36
    52-Week Range$3.08 to $9.82
    RSI (14 Days)39.8
    Average Volume (20 Days)57.70K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.66x current liabilities.

    Current Ratio1.66x
    Quick Ratio1.53x
    Interest Coverage-11.70x

    Returns and Efficiency

    Return on invested capital is -496.25% over the last 12 months, against a 5-year average of -90.57%.

    Return on Assets (ROA)-108.67%
    Return on Invested Capital (ROIC)-496.25%
    Return on Capital Employed (ROCE)-225.43%
    ROA (5Y Average)-72.01%
    ROIC (5Y Average)-90.57%
    Asset Turnover0.57x
    Inventory Turnover0.81x
    Receivables Turnover2.06x
    Cash Conversion Cycle391 days

    Scores

    VRCA has an Altman Z-Score of -14.11, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-14.11
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $22.89M over the last 12 months is down 25.75% from the 12 months before.

    Revenue$22.89M
    Revenue Growth (YoY)-25.75%
    Gross Profit$20.65M
    Operating Income-$42.17M
    Pretax Income-$43.32M
    Net Income-$43.32M
    EBITDA-$39.62M
    EBIT-$40.42M
    Reported EPS (TTM)-$2.08

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$14.39M
    Total Debt$12.41M
    Net Cash$1.99M
    Net Cash Per Share$0.09
    Working Capital$14.47M
    Shareholder Equity-$5.97M
    Total Assets$39.86M
    Total Liabilities$45.84M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$32.07M
    FCF Per Share-$1.87
    Depreciation and Amortization$798.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -184.23%.

    Gross Margin90.23%
    Operating Margin-184.23%
    Pretax Margin-189.23%
    Net Margin-189.23%
    EBITDA Margin-173.10%
    EBIT Margin-176.58%
    Gross Margin (5Y Average)92.74%

    Growth

    Revenue grew 57.93% a year over 3 years.

    Revenue Growth (3Y CAGR)+57.93%
    Book Value Per Share Growth (2Y CAGR)-26.22%
    Tangible Book Per Share Growth (2Y CAGR)-26.22%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-10 reverse split on Jul 25, 2025.

    Last Split DateJul 25, 2025
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 4 similar companies, VRCA has the 3rd highest P/S and the lowest ROIC.

    P/S Ratio2.9x vs 9.7x median
    ROIC-496.25% vs -109.22% median
    Revenue Growth (Trailing 4 Quarters, YoY)-25.75% vs -14.70% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.37% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.37%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VRCA

    What is VRCA's market cap?

    Verrica Pharmaceuticals has a market cap of $54.97M. Its enterprise value, which adds debt and subtracts cash, is $52.99M.

    How many shares of VRCA are outstanding?

    Verrica Pharmaceuticals has 21.31M shares outstanding. The count is up 124.50% from a year earlier.

    Does VRCA pay a dividend?

    No. Verrica Pharmaceuticals does not pay a dividend.

    How much debt does VRCA have?

    Verrica Pharmaceuticals has $12.41M of total debt and $14.39M of cash and equivalents, a net cash position of $1.99M.